A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Cause of death</td><td align="center">Number of patients (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Metastatic colorectal cancer </td><td align="center">8 (4.1)</td></tr><tr><td align="left">Pneumonia with septicaemia</td><td align="center">1 (0.5)</td></tr><tr><td align="left">Neutropenic fever </td><td align="center">1 (0.5)</td></tr><tr><td align="left">Haemorrhage of unknown origin</td><td align="center">1 (0.5)</td></tr><tr><td align="left">Toxicity related to chemotherapy </td><td align="center">1 (0.5)</td></tr><tr><td align="left">Total</td><td align="center"><b>12 (6)</b></td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>The percentage is calculated out of 195, the total number of patients in the survey’s cohort.<br/></td></tr></table>

Causes of death at 30 days after oxaliplatin treatment discontinuation.

Chemotherapy Research and Practice

tab5

Table 5

Table 5: A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer 

Table 5 | A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer 